JP2008534601A5 - - Google Patents

Download PDF

Info

Publication number
JP2008534601A5
JP2008534601A5 JP2008504297A JP2008504297A JP2008534601A5 JP 2008534601 A5 JP2008534601 A5 JP 2008534601A5 JP 2008504297 A JP2008504297 A JP 2008504297A JP 2008504297 A JP2008504297 A JP 2008504297A JP 2008534601 A5 JP2008534601 A5 JP 2008534601A5
Authority
JP
Japan
Prior art keywords
amino
ribofuranosyl
deoxy
imidazole
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008504297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008534601A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/011422 external-priority patent/WO2006105167A2/en
Publication of JP2008534601A publication Critical patent/JP2008534601A/ja
Publication of JP2008534601A5 publication Critical patent/JP2008534601A5/ja
Pending legal-status Critical Current

Links

JP2008504297A 2005-03-28 2006-03-28 患者における副作用を予防または減少するための方法、組成物および処方物 Pending JP2008534601A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66607105P 2005-03-28 2005-03-28
PCT/US2006/011422 WO2006105167A2 (en) 2005-03-28 2006-03-28 Methods, compositions, and formulations for preventing or reducing adverse effects in a patient

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012227810A Division JP2013010795A (ja) 2005-03-28 2012-10-15 患者における副作用を予防または減少するための方法、組成物および処方物
JP2012227809A Division JP2013010794A (ja) 2005-03-28 2012-10-15 患者における副作用を予防または減少するための方法、組成物および処方物

Publications (2)

Publication Number Publication Date
JP2008534601A JP2008534601A (ja) 2008-08-28
JP2008534601A5 true JP2008534601A5 (enExample) 2009-05-21

Family

ID=37054068

Family Applications (9)

Application Number Title Priority Date Filing Date
JP2008504297A Pending JP2008534601A (ja) 2005-03-28 2006-03-28 患者における副作用を予防または減少するための方法、組成物および処方物
JP2012227810A Pending JP2013010795A (ja) 2005-03-28 2012-10-15 患者における副作用を予防または減少するための方法、組成物および処方物
JP2012227809A Pending JP2013010794A (ja) 2005-03-28 2012-10-15 患者における副作用を予防または減少するための方法、組成物および処方物
JP2014254924A Active JP6122417B2 (ja) 2005-03-28 2014-12-17 患者における副作用を予防または減少するための方法、組成物および処方物
JP2016252553A Withdrawn JP2017057222A (ja) 2005-03-28 2016-12-27 患者における副作用を予防または減少するための方法、組成物および処方物
JP2019052531A Active JP7093739B2 (ja) 2005-03-28 2019-03-20 患者における副作用を予防または減少するための方法、組成物および処方物
JP2020110456A Pending JP2020152737A (ja) 2005-03-28 2020-06-26 患者における副作用を予防または減少するための方法、組成物および処方物
JP2022075916A Withdrawn JP2022093641A (ja) 2005-03-28 2022-05-02 患者における副作用を予防または減少するための方法、組成物および処方物
JP2025031494A Pending JP2025084893A (ja) 2005-03-28 2025-02-28 患者における副作用を予防または減少するための方法、組成物および処方物

Family Applications After (8)

Application Number Title Priority Date Filing Date
JP2012227810A Pending JP2013010795A (ja) 2005-03-28 2012-10-15 患者における副作用を予防または減少するための方法、組成物および処方物
JP2012227809A Pending JP2013010794A (ja) 2005-03-28 2012-10-15 患者における副作用を予防または減少するための方法、組成物および処方物
JP2014254924A Active JP6122417B2 (ja) 2005-03-28 2014-12-17 患者における副作用を予防または減少するための方法、組成物および処方物
JP2016252553A Withdrawn JP2017057222A (ja) 2005-03-28 2016-12-27 患者における副作用を予防または減少するための方法、組成物および処方物
JP2019052531A Active JP7093739B2 (ja) 2005-03-28 2019-03-20 患者における副作用を予防または減少するための方法、組成物および処方物
JP2020110456A Pending JP2020152737A (ja) 2005-03-28 2020-06-26 患者における副作用を予防または減少するための方法、組成物および処方物
JP2022075916A Withdrawn JP2022093641A (ja) 2005-03-28 2022-05-02 患者における副作用を予防または減少するための方法、組成物および処方物
JP2025031494A Pending JP2025084893A (ja) 2005-03-28 2025-02-28 患者における副作用を予防または減少するための方法、組成物および処方物

Country Status (14)

Country Link
US (3) US8993527B2 (enExample)
EP (3) EP2594273A1 (enExample)
JP (9) JP2008534601A (enExample)
KR (1) KR20070121026A (enExample)
CN (1) CN101184495B (enExample)
AU (1) AU2006230242B2 (enExample)
BR (1) BRPI0608654C1 (enExample)
CA (1) CA2602291C (enExample)
MX (1) MX2007012045A (enExample)
NO (1) NO342207B1 (enExample)
NZ (1) NZ561649A (enExample)
SG (3) SG10201704913RA (enExample)
WO (1) WO2006105167A2 (enExample)
ZA (1) ZA200708277B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007012045A (es) 2005-03-28 2008-01-16 Pericor Therapeutics Inc Composiciones y formulaciones para evitar o reducir efectos adversos a un paciente.
US20070082859A1 (en) * 2005-10-07 2007-04-12 Stover Richard R Formulations of AICA riboside
WO2008086341A1 (en) * 2007-01-09 2008-07-17 Pericor Therapeutics, Inc. Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
DE102008007216A1 (de) 2007-05-29 2008-12-11 Samsung Electro - Mechanics Co., Ltd., Suwon Gedruckte Leiterplatte und Herstellungsverfahren derselben
US9492468B2 (en) * 2008-10-03 2016-11-15 Pericor Therapeutics, Inc. Methods and compositions for treatment of acute heart failure
WO2011075391A1 (en) * 2009-12-15 2011-06-23 Schering Corporation Formulations of acadesine
US8489182B2 (en) 2011-10-18 2013-07-16 General Electric Company System and method of quality analysis in acquisition of ambulatory electrocardiography device data
WO2015108102A1 (ja) 2014-01-15 2015-07-23 国立大学法人 群馬大学 Atp可視化動物およびその用途
CA2977083A1 (en) 2014-02-20 2015-08-27 Kambiz Yadidi Dry powder formulations for inhalation
CN104140438B (zh) * 2014-06-11 2017-01-18 苏州景泓生物技术有限公司 5‑氨基‑4‑氨甲酰咪唑核苷碳环类似物的合成方法
CN107072947A (zh) * 2014-07-31 2017-08-18 奥迪托皮克股份有限公司 用于吸入的干粉制剂
WO2016176552A1 (en) 2015-04-30 2016-11-03 Otitopic Inc. Dry power formulations for inhalation
JP6937134B2 (ja) * 2016-11-21 2021-09-22 株式会社スタージェン 細胞内atp増強剤
WO2018092911A1 (ja) * 2016-11-21 2018-05-24 株式会社スタージェン 細胞内atp増強剤
JP7137225B2 (ja) * 2017-08-21 2022-09-14 国立大学法人三重大学 非ヒト哺乳類の脳梗塞モデルによる観察方法及び非ヒト哺乳類の脳梗塞モデルによる観察装置
US20220354855A1 (en) * 2019-10-09 2022-11-10 Mayo Foundation For Medical Education And Research Treatment for gastrointestinal disorders
EP3866176A1 (en) * 2020-02-17 2021-08-18 Siemens Healthcare GmbH Machine-based risk prediction for peri-procedural myocardial infarction or complication from medical data
US12369883B2 (en) 2020-06-19 2025-07-29 Ultrasound AI, Inc. Artificial intelligence system for determining clinical values through medical imaging
US11266376B2 (en) 2020-06-19 2022-03-08 Ultrasound Ai Inc. Premature birth prediction
WO2024073384A2 (en) * 2022-09-26 2024-04-04 The Penn State Research Foundation Anticoagulant-peptide nanogranules for thrombosis-actuated anticoagulation
WO2024192175A1 (en) * 2023-03-13 2024-09-19 Ultrasound AI, Inc. Artificial intelligence system for comprehensive medical diagnosis, prognosis, and treatment optimization through medical imaging

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1645976A1 (de) 1966-06-18 1971-01-21 Ajinomoto Kk Verfahren zur Herstellung von Adenosin und 2',3'-O-Isopropylidenadenosin
JPS4944349B1 (enExample) 1967-06-16 1974-11-27
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
AT350735B (de) 1976-08-06 1979-06-11 Hoffmann La Roche Verfahren zur herstellung von neuen ribo- furanosyl-imidazolderivaten
EP0066909A3 (en) 1981-05-15 1984-03-07 FISONS plc Imidazole derivatives, pharmaceutical compositions containing them and processes for their production
US4575498A (en) 1983-07-21 1986-03-11 Duke University Method for restoring depleted purine nucleotide pools
US5118601A (en) 1986-03-27 1992-06-02 The Regents Of The University Of California Method of screening purine nucleoside compounds or analogs for the ability to enhance the cellular synthesis and release of adenosine
US5030623A (en) 1986-03-27 1991-07-09 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
EP0623348A1 (en) 1986-03-27 1994-11-09 GRUBER, Harry, Edward The use of AICA riboside and ribavirin for the preparation of a medicament for the treatment of allergies
US5008251A (en) 1986-03-27 1991-04-16 The Regents Of The University Of California Method of treating autism
US4912092A (en) 1986-03-27 1990-03-27 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
US5082829A (en) * 1989-01-24 1992-01-21 Gensia Pharmaceuticals AICA riboside prodrugs
US5200525A (en) 1989-01-24 1993-04-06 Gensia Pharmaceuticals Anti-seizure compounds
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5132291A (en) 1989-01-24 1992-07-21 Gensia Pharmaceuticals, Inc. Antivirals and methods for increasing the antiviral activity of azt
US5646128A (en) 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5187162A (en) 1989-09-15 1993-02-16 Gensia Pharmaceuticals Methods of treating neurodegenerative conditions
IL99125A0 (en) * 1990-08-10 1992-07-15 Gensia Pharma Derivatives of imidazole analog of aica riboside and their use
IL99124A (en) * 1990-08-10 1998-02-22 Gensia Pharma Substituted imidazole analogs of aica riboside
US5777100A (en) 1990-08-10 1998-07-07 Gensia Inc. AICA riboside analogs
IL103294A0 (en) 1991-09-30 1993-05-13 Gensia Pharma Pharmaceutical compositions for preventing tissue damage associated with decreased blood flow
SG52739A1 (en) 1992-12-16 1998-09-28 Agouron Pharma Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds
IL108524A0 (en) 1993-02-03 1994-05-30 Gensia Inc Imidazodiazepine analogs
US5366960A (en) 1993-08-26 1994-11-22 Warner-Lambert Company Method of treating cerebral and cardiovascular disorders employing [R]3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidaz 0-[4,5-d][1,3]diazepin-8-ol
US5629298A (en) 1995-03-13 1997-05-13 University Of Massachusetts Medical Center Adenosine as a positive inotrop in the compromised heart
US5645128A (en) * 1995-06-05 1997-07-08 Schwall; Charles F. Fire safety grease seal
US5998386A (en) 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20040072138A1 (en) 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
US6103702A (en) 1999-05-24 2000-08-15 Board Of Trustees Of The University Of Illinois Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome
EP1492564A2 (en) 2001-10-31 2005-01-05 Université Libre de Bruxelles Amp-kinase agonists or adenosine pro-drugs as immuno-stimulating agents
ES2192495B1 (es) 2002-03-21 2005-02-16 Universidad De Barcelona Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).
MX2007012045A (es) 2005-03-28 2008-01-16 Pericor Therapeutics Inc Composiciones y formulaciones para evitar o reducir efectos adversos a un paciente.
US20070082859A1 (en) 2005-10-07 2007-04-12 Stover Richard R Formulations of AICA riboside
WO2008086341A1 (en) 2007-01-09 2008-07-17 Pericor Therapeutics, Inc. Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
WO2009094593A1 (en) 2008-01-25 2009-07-30 Foker John E Methods and compositions for inhibiting progression to chronic cardiac failure

Similar Documents

Publication Publication Date Title
JP2008534601A5 (enExample)
JP2023002662A5 (enExample)
EP3987291A1 (en) Methods of treating cancer
JP4804004B2 (ja) 関節軟骨細胞外マトリクス分解阻害剤
JP2021054865A (ja) ネココロナウイルス感染を処置する方法
CA2602291A1 (en) Treatments for preventing or reducing adverse effects in a patient having decreased left ventricular function
JP2009102342A5 (enExample)
JP2009524675A5 (enExample)
TW201219051A (en) Pharmaceutical composition
EP4267128A1 (en) Methods of treating cancer
BR112019018615B1 (pt) Composto antimicrobiano e sua composiqao farmaceutica
BR112020018601A2 (pt) Regime de dosagem de modulador de montagem de capsídeo
TW585762B (en) Pharmaceutical composition for prophylaxis or treatment of inflammatory bowel diseases
EP4267129A1 (en) Methods of treating cancer
EP4267126A1 (en) Methods of treating cancer
CN112469415A (zh) 用于预防或治疗非酒精性脂肪性肝炎的药物组合物
CN1341028A (zh) 美拉加林的新用途
TWI606826B (zh) 艾拉莫德或其鹽之用途
JP2022173353A (ja) 注腸剤
RU2008112181A (ru) Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3
PT1814517E (pt) Formulação parentérica líquida não aquosa de aceclofenac
HUP0203790A2 (hu) (6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére
EP4076442A1 (en) Pharmaceutical composition of cyclooxygenase - 2 inhibitors
US12502383B2 (en) Pharmaceutical composition of cyclooxygenase-2 inhibitors
WO2004009117A1 (ja) Ep2アゴニストを有効成分とする子宮収縮抑制剤